Roche Holding AG Stock Berne S.E.

Equities

ROG

CH0012032048

Pharmaceuticals

Delayed Berne S.E. 12:00:02 2024-04-17 EDT 5-day change 1st Jan Change
220.7 CHF -0.05% Intraday chart for Roche Holding AG -1.35% -9.54%

Financials

Sales 2024 * 60.47B 67.64B 92.45B Sales 2025 * 63.84B 71.4B 97.59B Capitalization 209B 234B 320B
Net income 2024 * 13.43B 15.02B 20.53B Net income 2025 * 14.85B 16.61B 22.71B EV / Sales 2024 * 3.69 x
Net Debt 2024 * 14.28B 15.97B 21.83B Net Debt 2025 * 9.19B 10.28B 14.06B EV / Sales 2025 * 3.42 x
P/E ratio 2024 *
15.1 x
P/E ratio 2025 *
13.8 x
Employees -
Yield 2024 *
3.78%
Yield 2025 *
3.88%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 66 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.7 CHF
Average target price
274 CHF
Spread / Average Target
+5.91%
Consensus